Table 4. The post-transformation gene mutations in the 7 patients that had NGS results.
| Gene mutations | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 |
|---|---|---|---|---|---|---|---|
| EGFR Exon 19 Deletion | X | X | X | X | X | X | |
| TP53 | X | X | X | X | X | X | X |
| RB1 loss | X | X | X | X | X | ||
| WNK1 | X | X | |||||
| APC | X | X | X | X | |||
| CCNE1 | X | X | X | ||||
| KMT2C | X | X | |||||
| CDK6 | X | X | |||||
| NF1 | X | X | |||||
| ATRX | X | X | |||||
| CARD11 EGFR amp | X | X | |||||
| MYC | X | X | |||||
| FGFR1 | X | X | |||||
| CDKN1B NOTCH1 KIF1B U2AF1L4 LRP1B ACVR1B TSC1 CUL4B TET2 CUX1 MTRR KMT2D | X | ||||||
| PIAS4 SRP68 TERT LMNA CBLB RNF139 PTPRT MALT1 RB1 CFTR CRLF2 AMER1 TOP2A SLC47A2 BCLAF1 ZMYM3 HSP90AA1 EGFR Copy number gain | X | ||||||
| KIT NKX2-1 NFKBIA BCL2L2 EGFR L858R STAG2 FOXP1 MPL RAC1 DOT1L SMAD3 EGFR L62R MET MAP2K1(MEK1) CIC BRCA2 CHD2 PMS2 ATM | X | ||||||
| PPARG CD22 RET BCL6 AKT2 IKZF1 CEBPA FAM46C DAXX KDM6A | X | ||||||
| ZRSR2 SMO FOXO1 CHEK2 KDR PIK3CB SMAD4 RANBP2 | X | ||||||
| FGFR3 RPTOR ABL2 IRS2 KLHL6 PDGFRB GNAS AURKA PTCH1 SMAD2 FLT3 KDM5A | X | ||||||
| KRAS CCND2 HRAS CCND1 PIK3CA GATA6 GPR124 AR ARID1B ESR1 | X |
WNK1 mutation was found in both patients 1 and 2 that had longer survival period. VUS genes are not shown. NGS, next-generation sequencing; WNK1, WNK lysine deficient protein kinase 1; VUS, variant of undetermined significance.